Trial Information

Summary: ABT-089, an investigational drug for the treatment of mild to moderate Alzheimer's Disease

The aim of the study is to determine whether the investigational drug ABT-089 is beneficial for enhancing cognition in treatment of mild to moderate Alzheimer's Disease. Participants will have to make study visits to the SHRI on a periodic basis for cognitive testing and physical evaluation.

Patient Inclusion Criteria:

• Must be within 55 to 90 years of age
• If taking acetylcholinesterase inhibitor, must have been on a stable dose upon entering the study
• Alzheimer's Disease must be mild to moderate
• Must have a caretaker

Patient Exclusion Criteria:

• Please contact SHRI to get details

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: June 1, 2008 at 6:37:28 AM